- Home
- ANGH vs KRON Comparison
ANGH vs KRON Comparison
Compare ANGH & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- KRON
- Stock Information
- Founded
- ANGH 2012
- KRON 2017
- Country
- ANGH United Arab Emirates
- KRON United States
- Employees
- ANGH N/A
- KRON N/A
- Industry
- ANGH Telecommunications Equipment
- KRON Medicinal Chemicals and Botanical Products
- Sector
- ANGH Consumer Discretionary
- KRON Health Care
- Exchange
- ANGH Nasdaq
- KRON Nasdaq
- Market Cap
- ANGH 47.5M
- KRON 54.4M
- IPO Year
- ANGH N/A
- KRON 2020
- Fundamental
- Price
- ANGH $0.55
- KRON $0.72
- Analyst Decision
- ANGH
- KRON Buy
- Analyst Count
- ANGH 0
- KRON 3
- Target Price
- ANGH N/A
- KRON $1.63
- AVG Volume (30 Days)
- ANGH 8.9K
- KRON 790.8K
- Earning Date
- ANGH 06-30-2025
- KRON 05-20-2025
- Dividend Yield
- ANGH N/A
- KRON N/A
- EPS Growth
- ANGH N/A
- KRON N/A
- EPS
- ANGH N/A
- KRON N/A
- Revenue
- ANGH $78,093,405.00
- KRON $9,848,000.00
- Revenue This Year
- ANGH N/A
- KRON N/A
- Revenue Next Year
- ANGH N/A
- KRON N/A
- P/E Ratio
- ANGH N/A
- KRON N/A
- Revenue Growth
- ANGH 88.72
- KRON 56.62
- 52 Week Low
- ANGH $0.42
- KRON $0.67
- 52 Week High
- ANGH $1.15
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- ANGH 42.39
- KRON 35.81
- Support Level
- ANGH $0.42
- KRON $0.67
- Resistance Level
- ANGH $0.65
- KRON $0.76
- Average True Range (ATR)
- ANGH 0.06
- KRON 0.05
- MACD
- ANGH -0.00
- KRON -0.01
- Stochastic Oscillator
- ANGH 55.75
- KRON 19.69
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with the catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner and is continuously licensing new content.
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.